Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow
Zacks Investment Research | Jul 28, 2021 01:57AM ET
Bristol-Myers Squibb Company (NYSE:BMY) industry 's decline of 1.5%.
Image Source: Zacks Investment Research
Second-quarter 2021 earnings of $1.93 per share beat the Zacks Consensus Estimate of $1.88 and increased from the year-ago quarter’s $1.63.
Total revenues of $11.7 billion also surpassed the Zacks Consensus Estimate of $11.2 billion and increased 16% from the year-ago period.
h3 Quarterly Details/h3Revenues increased 14% to $7.4 billion in the United States and 18% outside the country. Ex-U.S. revenues were up 10% when adjusted for foreign exchange impact.
Myeloma drug, Revlimid, along with the erstwhile Celgene (NASDAQ:CELG) acquisition, contributed $3.2 billion to the top line and was the top revenue generator for Bristol-Myers. Sales were up 11% for the drug year over year.
Eliquis maintained momentum for the company as sales increased 29% to $2.8 billion. We note that Bristol-Myers has a collaboration agreement with Pfizer the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Earnings estimates for Repligen for 2021 are up 5 cents in the past 60 days. The stock is up 23.3% in the year so far.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in a little more than 9 months and Nvidia (NASDAQ:NVDA) which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get The News You Want
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.